BRPI1011764A2 - composição farmacêutica, e, método para preparar uma composição farmacêutica - Google Patents

composição farmacêutica, e, método para preparar uma composição farmacêutica

Info

Publication number
BRPI1011764A2
BRPI1011764A2 BRPI1011764A BRPI1011764A BRPI1011764A2 BR PI1011764 A2 BRPI1011764 A2 BR PI1011764A2 BR PI1011764 A BRPI1011764 A BR PI1011764A BR PI1011764 A BRPI1011764 A BR PI1011764A BR PI1011764 A2 BRPI1011764 A2 BR PI1011764A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
pharmaceutical
composition
Prior art date
Application number
BRPI1011764A
Other languages
English (en)
Inventor
Chang-Shan Hsu
Jong-Jing Wang
Tsung-Hsin Lin
Wei-Hua Hao
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42992661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011764(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Publication of BRPI1011764A2 publication Critical patent/BRPI1011764A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI1011764A 2009-04-27 2010-04-27 composição farmacêutica, e, método para preparar uma composição farmacêutica BRPI1011764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17290109P 2009-04-27 2009-04-27
PCT/CN2010/000577 WO2010124525A1 (zh) 2009-04-27 2010-04-27 亲水性药物之自微乳化医药组合物及其制备

Publications (1)

Publication Number Publication Date
BRPI1011764A2 true BRPI1011764A2 (pt) 2016-03-29

Family

ID=42992661

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011764A BRPI1011764A2 (pt) 2009-04-27 2010-04-27 composição farmacêutica, e, método para preparar uma composição farmacêutica

Country Status (21)

Country Link
US (3) US20100273730A1 (pt)
EP (2) EP2425818A4 (pt)
JP (1) JP5753157B2 (pt)
KR (1) KR101759750B1 (pt)
CN (1) CN102427803B (pt)
AU (1) AU2010242461B2 (pt)
BR (1) BRPI1011764A2 (pt)
CA (1) CA2760039C (pt)
CO (1) CO6470799A2 (pt)
ES (1) ES2831037T3 (pt)
HK (1) HK1165701A1 (pt)
IL (1) IL215988A (pt)
MX (1) MX349014B (pt)
MY (1) MY174001A (pt)
NZ (1) NZ596657A (pt)
RU (1) RU2532362C2 (pt)
SG (1) SG175808A1 (pt)
TW (1) TWI461212B (pt)
UA (1) UA105042C2 (pt)
WO (1) WO2010124525A1 (pt)
ZA (1) ZA201108686B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3158991T1 (sl) 2010-01-28 2021-10-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
MX2012013872A (es) * 2010-06-02 2013-04-03 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
FI2827862T3 (fi) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Bendamustiinin formulaatioita
ES2943668T3 (es) 2012-03-20 2023-06-15 Eagle Pharmaceuticals Inc Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN105491886B (zh) 2013-08-27 2019-01-29 V·沃道里斯 苯达莫司汀医药组合物
WO2015104720A2 (en) * 2014-01-13 2015-07-16 Hetero Research Foundation Parenteral compositions of bendamustine
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
MX2017005883A (es) 2014-11-04 2017-11-28 Innopharmax Inc Administracion oral de farmacos inestables o deficientemente absorbidos.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9943513B1 (en) * 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10335405B1 (en) * 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
AU2017273495B2 (en) * 2016-06-02 2023-01-12 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019051437A1 (en) * 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
AU2021257738A1 (en) * 2020-04-13 2022-05-19 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation
CN112006986A (zh) * 2020-08-07 2020-12-01 厦门大学 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用
CN114397381A (zh) * 2021-12-17 2022-04-26 南京农业大学 一种沼液中阿莫西林的提取及含量检测方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0736041B1 (en) * 1993-11-17 2006-02-08 Athena Neurosciences, Inc. Transparent liquid for encapsulated drug delivery
AU742250B2 (en) * 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
WO2003093344A1 (en) * 2002-05-03 2003-11-13 Janssen Pharmaceutica N.V. Polymeric microemulsions
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1593405A (zh) * 2004-07-09 2005-03-16 沈阳药科大学 一种氟康唑液体型组方及其制剂
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JPWO2007089043A1 (ja) 2006-02-03 2009-06-25 武田薬品工業株式会社 リポソーム製剤
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs

Also Published As

Publication number Publication date
AU2010242461B2 (en) 2016-05-19
AU2010242461A1 (en) 2011-12-15
SG175808A1 (en) 2011-12-29
RU2532362C2 (ru) 2014-11-10
RU2011148140A (ru) 2013-06-10
CN102427803A (zh) 2012-04-25
EP2425818A4 (en) 2012-10-24
KR101759750B1 (ko) 2017-07-31
TW201041597A (en) 2010-12-01
EP2425818A1 (en) 2012-03-07
ZA201108686B (en) 2012-08-29
US20190275006A1 (en) 2019-09-12
ES2831037T3 (es) 2021-06-07
JP5753157B2 (ja) 2015-07-22
CA2760039C (en) 2017-05-16
EP3045165A2 (en) 2016-07-20
NZ596657A (en) 2014-01-31
KR20120015330A (ko) 2012-02-21
CO6470799A2 (es) 2012-06-29
HK1165701A1 (en) 2012-10-12
CN102427803B (zh) 2015-06-10
MX349014B (es) 2017-07-06
IL215988A (en) 2016-12-29
MY174001A (en) 2020-03-03
TWI461212B (zh) 2014-11-21
EP3045165A3 (en) 2016-09-21
CA2760039A1 (en) 2010-11-04
JP2012524820A (ja) 2012-10-18
US20100273730A1 (en) 2010-10-28
US20150196537A1 (en) 2015-07-16
MX2011011374A (es) 2012-02-08
IL215988A0 (en) 2012-01-31
EP3045165B1 (en) 2020-09-23
WO2010124525A1 (zh) 2010-11-04
UA105042C2 (uk) 2014-04-10

Similar Documents

Publication Publication Date Title
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112012009609A2 (pt) método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BR112014015042A8 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI1015095A2 (pt) composição, processos para preparar uma composição e um material de poli-isocianurato , e, material de poli-isocianurato
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI1008598A2 (pt) composição farmacêutica para inalação
BR112012016912A2 (pt) composição de gel de diagnóstico, método para preparar uma composição de gel de diagnóstico
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0817727A2 (pt) composição de graxa lubrificante, e, método para preparar uma composição de graxa
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BRPI1007160A2 (pt) Método para esterilizar um material
BR112012015100A2 (pt) composição de polímero modificado, artigo e método para produzir uma composição de polímero modificado
BR112012014023A2 (pt) mistura polimérica, artigo e método para preparar uma mistura polimérica
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]